ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
Fiscal 2025 also underscored how concentrated the business remains in the United States, even as select franchises broaden the portfolio. With new commercial initiatives and product enhancements in motion, ANIP enters 2026 with multiple levers aimed at sustaining momentum. ANIP's Revenue Mix Shifts Toward Rare Disease Fiscal 2025 total revenue reached $883.4 million, with Rare Disease and Brands contributing $484.0 million, or 54.8% of the total. Generics and Other supplied the remaining $399.4 million, or 45.2%. Within Rare Disease and Brands, Cortrophin Gel delivered $347.8 million, while Iluvien and Yutiq contributed $74.9 million. This mix highlights how the specialty portfolio has become the core growth narrative, anchored by a single high-impact product and supported by an ophthalmology platform. Geographically, fiscal 2025 revenue was primarily U.S.-derived, with $852.4 million generated domestically versus $30.9 million from international operations and partnerships.
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT ExclusivityGlobeNewswire
- ANI Pharmaceuticals (ANIP) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- 1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release CapsulesGlobeNewswire
ANIP
Earnings
- 2/27/26 - Beat
ANIP
Sec Filings
- 4/13/26 - Form 4
- 4/9/26 - Form ARS
- 4/9/26 - Form DEFA14A
- ANIP's page on the SEC website